608 related articles for article (PubMed ID: 30885340)
1. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
[TBL] [Abstract][Full Text] [Related]
2. IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells.
Rodrigues FS; Miranda VS; Carneiro-Lobo TC; Scalabrini LC; Kruspig B; Levantini E; Murphy DJ; Bassères DS
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823550
[TBL] [Abstract][Full Text] [Related]
3. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
[TBL] [Abstract][Full Text] [Related]
4. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
5. Targeting the KRAS, p38α, and NF-κB in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitor.
Zarredar H; Pashapour S; Farajnia S; Ansarin K; Baradaran B; Ahmadzadeh V; Safari F
J Cell Biochem; 2019 Jun; 120(6):10670-10677. PubMed ID: 30656741
[TBL] [Abstract][Full Text] [Related]
6. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
7. Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.
Zhang Y; Lapidus RG; Liu P; Choi EY; Adediran S; Hussain A; Wang X; Liu X; Dan HC
Mol Cancer Ther; 2016 Jul; 15(7):1504-14. PubMed ID: 27196761
[TBL] [Abstract][Full Text] [Related]
8. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
Dos Santos EO; Carneiro-Lobo TC; Aoki MN; Levantini E; Bassères DS
Mol Cancer; 2016 Feb; 15():12. PubMed ID: 26842935
[TBL] [Abstract][Full Text] [Related]
9. Distinct roles for IκB kinases alpha and beta in regulating pulmonary endothelial angiogenic function during late lung development.
Iosef C; Liu M; Ying L; Rao SP; Concepcion KR; Chan WK; Oman A; Alvira CM
J Cell Mol Med; 2018 Sep; 22(9):4410-4422. PubMed ID: 29993183
[TBL] [Abstract][Full Text] [Related]
10. Dysregulated Kras/YY1/ZNF322A/Shh transcriptional axis enhances neo-angiogenesis to promote lung cancer progression.
Lin CC; Kuo IY; Wu LT; Kuan WH; Liao SY; Jen J; Yang YE; Tang CW; Chen YR; Wang YC
Theranostics; 2020; 10(22):10001-10015. PubMed ID: 32929330
[TBL] [Abstract][Full Text] [Related]
11. IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity.
Bassères DS; Ebbs A; Cogswell PC; Baldwin AS
Genes Cancer; 2014 Apr; 5(1-2):41-55. PubMed ID: 24955217
[TBL] [Abstract][Full Text] [Related]
12. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer.
Chen C; Xu ZQ; Zong YP; Ou BC; Shen XH; Feng H; Zheng MH; Zhao JK; Lu AG
Cell Death Dis; 2019 Feb; 10(3):178. PubMed ID: 30792394
[TBL] [Abstract][Full Text] [Related]
13. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
14. IκB Kinase α Is Required for Development and Progression of
Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells.
Di Martile M; Gabellini C; Desideri M; Matraxia M; Farini V; Valentini E; Carradori S; Ercolani C; Buglioni S; Secci D; Andreazzoli M; Del Bufalo D; Trisciuoglio D
J Exp Clin Cancer Res; 2020 Jun; 39(1):103. PubMed ID: 32498717
[TBL] [Abstract][Full Text] [Related]
16. Tpl2 inhibitors thwart endothelial cell function in angiogenesis and peritoneal dissemination.
Lee WJ; Lan KH; Chou CT; Yi YC; Chen WC; Pan HC; Peng YC; Wang KB; Chen YC; Chao TH; Tien HR; Sheu WH; Sheu ML
Neoplasia; 2013 Sep; 15(9):1036-48. PubMed ID: 24027429
[TBL] [Abstract][Full Text] [Related]
17. Endothelial-specific loss of IKKβ disrupts pulmonary endothelial angiogenesis and impairs postnatal lung growth.
Rao S; Liu M; Iosef C; Knutsen C; Alvira CM
Am J Physiol Lung Cell Mol Physiol; 2023 Sep; 325(3):L299-L313. PubMed ID: 37310763
[TBL] [Abstract][Full Text] [Related]
18. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
19. The antitumor effect of a novel angiogenesis inhibitor (an octahydronaphthalene derivative) targeting both VEGF receptor and NF-κB pathway.
Watari K; Nakamura M; Fukunaga Y; Furuno A; Shibata T; Kawahara A; Hosoi F; Kuwano T; Kuwano M; Ono M
Int J Cancer; 2012 Jul; 131(2):310-21. PubMed ID: 21826646
[TBL] [Abstract][Full Text] [Related]
20. Arenobufagin, isolated from toad venom, inhibited epithelial-to-mesenchymal transition and suppressed migration and invasion of lung cancer cells via targeting IKKβ/NFκB signal cascade.
Zhao J; Zhang Q; Zou G; Gao G; Yue Q
J Ethnopharmacol; 2020 Mar; 250():112492. PubMed ID: 31866511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
